Typhoid Vaccine Live Ty21a

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Typhoid Vaccine Live Ty21a
Accession Number
DB11050
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Description

Salmonella typhi Ty21a live antigen is a live attenuated vaccine for oral administration only. It contains the attenuated strain Salmonella typhi Ty21a. The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by Salmonella typhi by inducing a local immune response in the intestinal tract.

Synonyms
  • Salmonella enterica subsp. enterica serovar typhi
  • Salmonella typhi Ty21a live antigen
  • Typhoid vaccine (salmonella typhi Ty21a)
  • Typhoid Vaccine Live Ty21a
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VivotifCapsule, coated6000000000 [CFU]/1OralPaxvax Berna Gmbh1992-03-16Not applicableUs
VivotifCapsule, delayed release10 bOralPaxvax Berna Gmbh1993-01-01Not applicableCanada
VivotifCapsule, coated2 [CFU]/1[CFU]OralA-S Medication Solutions1992-03-16Not applicableUs
VivotifCapsule, coated6000000000 [CFU]/1OralA-S Medication Solutions1992-03-16Not applicableUs
Vivotif LPowder10 bOralBerna Biotech Ltd1997-11-012015-11-01Canada
Vivotif-BCapsule2 [CFU]/1OralRebel Distributors Corp1989-12-15Not applicableUs
Categories
UNII
0MZI008M96
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Salmonella typhi ty21a live antigen.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Salmonella typhi ty21a live antigen.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Salmonella typhi ty21a live antigen.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Salmonella typhi ty21a live antigen.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Salmonella typhi ty21a live antigen.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Salmonella typhi ty21a live antigen.
AbituzumabThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Salmonella typhi ty21a live antigen.
AdalimumabThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Adalimumab.
AdalimumabThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Adalimumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911093
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingPreventionSalmonella Typhi Infection1
4Enrolling by InvitationBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4RecruitingPreventionHealthy Volunteers1
Not AvailableCompletedNot AvailableSalmonella Typhi Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Capsule, coatedOral2 [CFU]/1[CFU]
Capsule, coatedOral6000000000 [CFU]/1
Capsule, delayed releaseOral10 b
PowderOral10 b
CapsuleOral2 [CFU]/1
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:05 / Updated on October 16, 2018 08:42